Space startup Varda raises $187 million in funding to make drugs in orbit

Space startup Varda raises 7 million in funding to make drugs in orbit


Pavlo Gonchar | Lightrocket | Getty Images

Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space.

The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. It brought the total capital Varda’s raised to $329 million.

“By expanding, we can support work on more complex molecules and ultimately increase cadence to achieve the turnaround times the pharmaceutical industry expects,” Chief Science Officer Adrian Radocea said in a press release Thursday.

Varda’s main mission is to launch and return drugs made in space. The startup has said the medicines crystallize differently in orbit due to the gravity differences, which would allow it to complete drugs that are currently difficult to manufacture.

In 2024, the space startup’s W-Series 1 capsule received FAA approval to return after successfully creating the drug Ritonavir the previous year.

So far, Varda said the company has been able to complete three space launches. Now, a fourth is in orbit, and the company expects to launch a fifth by the end of the year. Varda’s system uses Rocket Lab’s Photon spacecraft for its operation and adds its manufacturing module and a heatshield-protected capsule.

“With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world’s first microgravity-enabled drug formulation,” said Varda CEO Will Bruey.

Varda Space Industries is the first company to process materials outside the International Space Station.

Recently, the space company has also operated a testbed for the U.S. government to use the W-series reentry vehicles to advance technology.

Varda said it has expanded into Huntsville, Alaska, and opened a laboratory in El Segundo, California, to begin work to crystallize more drugs.

“Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy,” Radocea said.



Source

As American Girl turns 40, Mattel grapples with bringing dolls into a new era
Business

As American Girl turns 40, Mattel grapples with bringing dolls into a new era

The original six American Girl historical characters — Kirsten Larson, Samantha Parkington, Molly McIntire, Felicity Merriman, Addy Walker and Josefina Montoya — are displayed at the brand’s flagship store, Luke Fountain The flagship American Girl Place at Rockefeller Center in New York City feels frozen in time. The air smells faintly of vanilla. Young girls […]

Read More
Under mounting toy pressures, Hasbro has a secret sauce that Mattel hasn’t matched
Business

Under mounting toy pressures, Hasbro has a secret sauce that Mattel hasn’t matched

The gap is widening between rival toy makers Hasbro and Mattel — thanks in part to a 30-year-old trading card game. The toy giants have flip-flopped dominance in the space for decades, jockeying for the most coveted master licenses to put new fan favorites — Disney princesses and “Star Wars” characters among them — on […]

Read More
Illiquid loans, investor demands: Blue Owl’s software lending triggers another quake in private credit
Business

Illiquid loans, investor demands: Blue Owl’s software lending triggers another quake in private credit

Blue Owl BDC’s CEO Craig Packer speaks during an interview with CNBC on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., Nov. 19, 2025. Brendan McDermid | Reuters The latest tremor in the private credit world involved a deal that should’ve been reassuring to markets. Blue Owl, a direct […]

Read More